{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:04:12Z","timestamp":1790377452412,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nmd.2026.106338","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:23:34Z","timestamp":1768926214000},"page":"106338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Meeting report: Expanding access to advanced cardiac therapies, including ventricular assist devices (VADs) and heart transplantation in muscular dystrophy"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-3150","authenticated-orcid":false,"given":"Seth A.","family":"Hollander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.nmd.2026.106338_bib0001","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"10119","key":"10.1016\/j.nmd.2026.106338_bib0002","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.nmd.2026.106338_bib0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.nmd.2026.106338_bib0004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.28075","article-title":"Survival among patients receiving eteplirsen for up to 8\u2009years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls","volume":"70","author":"Iff","year":"2024","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2026.106338_bib0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.106338_bib0006","article-title":"Multi-modal benefits of deramiocel (CAP-1002) in late-stage patients with DMD: a new treatment approach to target skeletal and cardiac muscle pathogenesis (HOPE 2-OLE trial: 36-month data)","author":"Craig","year":"2024","journal-title":"World Muscle Society"},{"issue":"10329","key":"10.1016\/j.nmd.2026.106338_bib0007","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","article-title":"Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"McDonald","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.nmd.2026.106338_bib0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2026.106338_bib0009","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ahj.2007.05.014","article-title":"Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up","volume":"154","author":"Duboc","year":"2007","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.nmd.2026.106338_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013501","article-title":"Stabilization of early duchenne cardiomyopathy with aldosterone inhibition: results of the Multicenter AIDMD trial","volume":"8","author":"Raman","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.nmd.2026.106338_bib0011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.nmd.2026.106338_bib0012","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.nmd.2026.106338_bib0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.nmd.2026.106338_bib0014","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacbts.2021.11.004","article-title":"Cardiovascular disease in Duchenne muscular dystrophy: overview and insight into novel therapeutic targets","volume":"7","author":"Schultz","year":"2022","journal-title":"JACC Basic Transl Sci"},{"issue":"10","key":"10.1016\/j.nmd.2026.106338_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103186","article-title":"Duchenne Dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies","volume":"9","author":"Adorisio","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.nmd.2026.106338_bib0016","first-page":"555","article-title":"Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy","volume":"28","author":"Morfino","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"21","key":"10.1016\/j.nmd.2026.106338_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011902","article-title":"Antagonism of the thromboxane-prostanoid receptor as a potential therapy for cardiomyopathy of muscular dystrophy","volume":"8","author":"West","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.nmd.2026.106338_bib0018","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacbts.2019.06.006","article-title":"Gene therapy rescues cardiac dysfunction in duchenne muscular dystrophy mice by elevating cardiomyocyte deoxy-adenosine triphosphate","volume":"4","author":"Kolwicz","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"10.1016\/j.nmd.2026.106338_bib0019","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cvr\/cvaa211","article-title":"Inflammation and cardiovascular diseases: lessons from seminal clinical trials","volume":"117","author":"Liberale","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.nmd.2026.106338_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148554","article-title":"Therapeutic targets for cardiac fibrosis: from old school to next-gen","volume":"132","author":"Travers","year":"2022","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.nmd.2026.106338_bib0021","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00246-021-02807-7","article-title":"Current practices in treating cardiomyopathy and heart failure in duchenne muscular dystrophy (DMD): understanding care practices in order to optimize DMD heart failure through ACTION","volume":"43","author":"Villa","year":"2022","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"10.1016\/j.nmd.2026.106338_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001338","article-title":"Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy","volume":"4","author":"Tandon","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nmd.2026.106338_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040","article-title":"Cardiovascular measures of all-cause mortality in duchenne muscular dystrophy","author":"Soslow","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.nmd.2026.106338_bib0024","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.nmd.2026.106338_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16267","article-title":"Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids","volume":"31","author":"Schiava","year":"2024","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.nmd.2026.106338_bib0026","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.nmd.2015.09.012","article-title":"Development and psychometric analysis of the duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)","volume":"25","author":"Landfeldt","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106338_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ppedcard.2023.101639","article-title":"Major adverse dystrophinopathy events (MADE) score as marker of cumulative morbidity and risk for mortality in boys with duchenne muscular dystrophy","volume":"69","author":"Kaufman","year":"2023","journal-title":"Prog Pediatr Cardiol"},{"issue":"10","key":"10.1016\/j.nmd.2026.106338_bib0028","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.nmd.2016.07.010","article-title":"Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C","volume":"26","author":"Villa","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.nmd.2026.106338_bib0029","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00246-024-03459-z","article-title":"Wireless pulmonary artery pressure monitor implantation in a patient with duchenne muscular dystrophy","volume":"45","author":"Sisson","year":"2024","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.nmd.2026.106338_bib0030","article-title":"Initial multicenter experience with ventricular assist devices in children and young adults with muscular dystrophy: an ACTION registry analysis","author":"Nandi","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.nmd.2026.106338_bib0031","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ijcard.2012.04.009","article-title":"Left ventricular assist device in Duchenne cardiomyopathy: can we change the natural history of cardiac disease?","volume":"161","author":"Amodeo","year":"2012","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.nmd.2026.106338_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.nmd.2026.106338_bib0033","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.28072","article-title":"Cardiac atrial pathology in Duchenne muscular dystrophy","volume":"69","author":"Greiner","year":"2024","journal-title":"Muscle Nerve"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:36:00Z","timestamp":1773704160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"alternative-id":["S0960896626000064"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106338","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting report: Expanding access to advanced cardiac therapies, including ventricular assist devices (VADs) and heart transplantation in muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106338"}}